All In Biotech

NDA 216830 · Dr Reddys Labs SA

Phenylephrine Hydrochloride In 0.9% Sodium Chloride

Phenylephrine Hydrochloride · Intravenous · alpha-1 Adrenergic Agonist

Last checked: Nov 19, 2026Latest source record: May 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

May 30, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

627

74 Phase 3, 25 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 31, 2026.

Phenylephrine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Phenylephrine Hydrochloride in 0.9% Sodium Chloride Injection is an alpha-1 adrenergic receptor agonist indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation, in the setting of anesthesia ( 1 )

Mechanism: Phenylephrine hydrochloride is an α-1 adrenergic receptor agonist.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 30, 2025 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE · PHENYLEPHRINE HYDROCHLORIDE 20MG/250ML (0.08MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Phenylephrine" as an intervention, any sponsor and status, largest first.

All 627 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,179 on PubMed

Sponsor: Dr Reddys Labs SA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.